Results 51 to 60 of about 442,345 (289)

Development and validation of prostate-specific membrane antigen–adjusted Prostate Imaging Reporting and Data System: A new approach to enhancing the accuracy of diagnosing treatment-naïve primary prostate cancer

Asian Journal of Urology
Objective: The diagnostic efficacy of hybrid positron emission tomography (PET)/MRI in detecting primary prostate cancer (PCa) is limited due to the lack of a quantitative integrated analysis.
Xiaoyuan Li, Jieping Song, Xiaochen Yao, Zhenyu Zhao, Qing Zhang, Rushuai Li, Pengjun Zhang, Wenyu Wu, Hongwei Sun, Shuyue Ai, Fengjiao Yang, Hongqian Guo, Kuangyu Shi, Ali Afshar-Oromieh, Longjiang Zhang, Guangming Lu, Ali Cahid Civelek, Feng Wang   +17 more
doaj   +1 more source

Predicting prostate cancer in men with PSA levels of 4–10 ng/mL: MRI-based radiomics can help junior radiologists improve the diagnostic performance

Scientific Reports, 2023
To develop MRI-based radiomics model for predicting prostate cancer (PCa) in men with prostate-specific antigen (PSA) levels of 4–10 ng/mL, to compare the performance of radiomics model and PI-RADS v2.1, and to further verify the predictive ability of ...
Jian-Guo Zhong, Lin Shi, Jing Liu, Fang Cao, Yan-Qing Ma, Yang Zhang   +5 more
doaj   +1 more source

A context‐dependent modulatory role for eIF6 in acquired resistance to vemurafenib in melanoma

FEBS Letters, EarlyView.
Acquired resistance to vemurafenib upregulates the translation factor eIF6 in melanoma cells. Silencing eIF6 in resistant cells reduces proliferation and partially restores drug sensitivity, whereas its overexpression increases sensitivity across melanoma lines regardless of BRAF status, via modulation of mTOR, S6K, and MAPK signaling.
George Kyriakopoulos, Antonia Petropoulou, Alexandra Anastogianni, Angelina Bania, Vassilis Stamatakis, Argyris Alexiou, Chi‐Ping Day, Glenn Merlino, Katerina Grafanaki, Constantinos Stathopoulos   +9 more
wiley   +1 more source

Comparison of diagnostic performance and inter-reader agreement between PI-RADS v2.1 and PI-RADS v2: systematic review and meta-analysis

, 2022
To perform a systematic review and meta-analysis comparing diagnostic performance and inter reader agreement between PI-RADS v. 2.1 and PI-RADS v. 2 in the detection of clinically significant prostate cancer (csPCa)
Lee, Chau Hung, Vellayappan, Balamurugan, Tan, Cher Heng   +2 more
core   +1 more source

PI-RADS 2.1 und strukturierte Befundung der Magnetresonanztomographie der Prostata [PDF]

, 2021
CLINICAL/METHODOLOGICAL ISSUE The detection of clinically significant prostate cancers while simultaneously avoiding over-diagnosing tumors with low malignant potential is a challenge in clinical practice.
Donati, Olivio F, Hötker, Andreas
core   +1 more source

Variation in Clinically Significant Prostate Cancer on Fusion Biopsy of PI-RADS 3–5 Lesions Based on Ethnicity

American Journal of Men's Health
Our aim is to investigate the prevalence of clinically significant prostate cancer (Gleason score 3+4 or higher) on fusion biopsy for Prostate Imaging Reporting and Data System (PI-RADS) 3–5 lesions based on ethnicity.
Beth Edelblute, Ahmed Aly, Zhe Jing, Abdul WasayMahmood, Kara Watts, Alex Sankin, Pedro Maria, Khurshid Guru, Ahmed Aboumohamed   +8 more
doaj   +1 more source

Follow-up of men with a PI-RADS 4/5 lesion after negative MRI/Ultrasound fusion biopsy

Scientific Reports, 2022
Magnetic resonance imaging/Ultrasound (MRI/US) fusion targeted biopsy (TB) in combination with a systematic biopsy (SB) improves cancer detection but limited data is available how to manage patients with a Prostate Imaging-Reporting and Data System (PI ...
Kira Kornienko, Miriam Reuter, Andreas Maxeiner, Karsten Günzel, Beatrice Kittner, Maximilian Reimann, Sebastian L. Hofbauer, Laura E. Wiemer, Robin Heckmann, Patrick Asbach, Johann Jakob Wendler, Martin Schostak, Thorsten Schlomm, Frank Friedersdorff, Hannes Cash   +14 more
doaj   +1 more source

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

RADS-2 measurement invariance by gender.

, 2023
Depression in young people is considered a public health problem, given that it affects their personal, social, and academic lives; therefore, early detection of depressive symptoms is of importance for a favorable prognosis. This study aimed to estimate
Miguel Basauri Delgado (15909758), Jacksaint Saintila (11548458), Cristian Ramos-Vera (11922568), Gleni Quispe Callo (15909755), José Vallejos Saldarriaga (15909761)   +4 more
core   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source